Joseph Busky manages global financial operations, planning and reporting for QuidelOrtho. He has more than 30 years of experience in corporate finance roles for large, global companies across diagnostics, medical devices, telecom and marketing services industries.

Prior to joining Ortho Clinical Diagnostics in July 2020, Mr. Busky served as Chief Financial Officer for Vyaire Medical, Inc., a global medical device company. He has also served as Chief Financial Officer of FDH Velocitel, Chief Financial Officer of InnerWorkings, Inc., and also held corporate and divisional finance roles for a combined 11 years at Siemens Medical Solutions Diagnostics/Dade Behring Holdings, Inc., Bayer Diagnostics and Diagnostic Products Corporation, including serving as Chief Accounting Officer at Dade Behring.

Mr. Busky holds an MBA with a finance concentration, as well as a BBA in Accounting, from Loyola University in Baltimore. He also has a CPA certification in Maryland.

Lee Bowman oversees all aspects of people, culture and human resources strategy at QuidelOrtho. His career spans more than 25 years of leadership experience across various industries, and his accomplishments are marked by a strong commitment to talent management and fostering inclusive, dynamic workplace cultures.

Mr. Bowman previously served as Senior Vice President and Chief People Officer at RadNet, where he led transformative initiatives in workforce engagement, diversity and inclusion, and leadership development. His expertise was further honed through significant roles at Edwards Lifesciences, Levi Strauss & Co. and Target, where he spearheaded high-impact human resource strategies that prioritized team development and organizational growth.

Mr. Bowman holds a bachelor’s degree in psychology from Towson University and an MBA from San Diego State University.

Michelle Hodges heads the company’s legal and compliance group, supporting global business and overseeing all legal and governance matters. She has over two decades of legal experience, specializing in advising public and private companies on mergers and acquisitions, strategic investments, securities law and corporate governance.

Ms. Hodges served as Senior Vice President, General Counsel of Quidel Corp. from December 2020 to May 2022. Prior to joining Quidel, Ms. Hodges was a corporate lawyer with the international law firm of Gibson, Dunn & Crutcher LLP and served as a Partner of the firm for 16 years.

Ms. Hodges received her JD and MBA from the University of California, Los Angeles. She earned a bachelor’s degree in horticultural science with honors from Massey University, New Zealand.

Phil McLellan leads all aspects of quality, manufacturing and operations, focusing on delivering high-quality products with great efficiency, enhancing scalability and supporting growth initiatives across the company. He brings over 25 years of leadership experience in operations and manufacturing within the life sciences and automotive industries.

Mr. McLellan has led transformative efforts in the company to expand operational scope and capabilities. Prior to his current role, he spent 11 years at Thermo Fisher Scientific, where he led division operations teams for laboratory consumables, genetic analysis and bioproduction businesses, spearheading initiatives to optimize performance and innovation. He also held multiple global manufacturing roles over 12 years with Toyota Motor Manufacturing, where he honed his expertise in lean manufacturing and process improvement.

Mr. McLellan holds a bachelor’s degree in mechanical engineering from the Georgia Institute of Technology.

Jonathan Siegrist is responsible for the company’s global R&D strategy, driving innovation and advancing next-generation diagnostic solutions. He brings over 15 years of leadership experience in the biotechnology and diagnostics industries, with a focus on molecular diagnostics, microfluidic platforms and biomedical engineering.

Before joining QuidelOrtho, Mr. Siegrist served as Chief Technology Officer and Head of Assay Research and Development at Cepheid. Throughout his career, he has been recognized for his ability to lead complex, multidisciplinary teams while fostering a culture of creativity and innovation.

Mr. Siegrist holds a PhD and Master of Science in biomedical engineering from the University of California, Irvine, and a Bachelor of Science in electrical engineering from the University of California, Los Angeles.

Erich Wolff leads QuidelOrtho’s global strategy, business development, corporate development, portfolio management and government relations functions. He plays a central role in advancing the company’s long-term growth strategy and identifying opportunities to drive enterprise value across the organization.

Mr. Wolff brings over 20 years of leadership experience in the healthcare, MedTech and diagnostics sectors, with deep expertise in mergers and acquisitions, portfolio optimization, and corporate transformation. Prior to joining QuidelOrtho, he served as Buyouts Lead for MedTech and Life Sciences Tools & Diagnostics at Partners Group, a global private equity firm. He has also held senior executive roles at BD and Medtronic.

Known for his ability to align strategic investments with business priorities, Mr. Wolff is recognized for building high-performing teams and delivering results in complex, global environments.

Mr. Wolff holds a Bachelor of Business Administration in Finance and Economics from the University of Wisconsin–Milwaukee.

Andrew Corkum heads the international business for QuidelOrtho across Europe, Middle East, Africa and Latin America regions. He brings more than 30 years of international sales and operational leadership experience with expertise in transfusion medicine and in vitro diagnostics.

Mr. Corkum joined the company in 2017 as President of Commercial Operations in Canada. Previously, he was with Immucor as Vice President of Sales for Europe and Canada. He began his career in immunodiagnostics with Dominion Biologicals. Before his current role with QuidelOrtho, he served as global head of the clinical labs and transfusion medicine business units where he oversaw all activities related to portfolio strategy and innovation, product development, life cycle management, market development, marketing and portfolio growth.

Mr. Corkum received a bachelor’s degree in business administration from Mount Saint Vincent University and an MBA in international business from Athabasca University.

Bryan Hanson is responsible for defining and executing the strategic vision of the QuidelOrtho clinical labs and transfusion medicine portfolios. He is accountable for the management of all functions of the business unit in all regions, as well as leading strategy to grow revenue, economic profit and market share globally.

Mr. Hanson has held several leadership roles during his more than 17 years with QuidelOrtho and its legacy companies. Prior to his current position, he was President of North America Commercial Operations where he led the transformation and integration of the organization to accelerate revenue. He also served in sales, marketing and operational roles with Johnson & Johnson and Ortho Clinical Diagnostics prior to the formation of QuidelOrtho. He began his career in sales with FedEx Corporation.

Mr. Hanson earned a bachelor's degree in business administration from University of North Dakota and a certificate in strategic marketing management from The Wharton School of the University of Pennsylvania.

Audra Jones leads commercial business strategy for the North America region and is responsible for driving the growth and performance of company’s largest region. With more than 20 years of diverse sales, marketing and leadership experience in the in vitro diagnostics and pharmaceutical industries, she has a demonstrated record of success achieving operational and revenue targets.

Ms. Jones joined the company in 2008 as a Customer Business Manager with Johnson & Johnson. After divestiture and the formation of Ortho Clinical Diagnostics, she held several key leadership positions including Vice President North America Marketing and Commercial Enablement, Area Sales Director, General Manager of Canada and U.S. Director Government Sales.

She began her career as an independent business owner prior to entering the pharmaceutical industry at Merck and later Ortho-McNeil. Ms. Jones earned a Bachelor of Science degree from Tarleton State University.

Iris Lin leads the international business for QuidelOrtho in Japan, ASPAC and China. With over 20 years of global experience spanning sales, marketing, business development, R&D and portfolio management in the in vitro diagnostics industry, she brings a proven approach to cross-cultural collaboration, product development and commercial excellence. In her role as the head of JAPAC, she oversees commercial, operational and financial performance in the region.

Ms. Lin began her career with Johnson & Johnson Medical China as District Sales Manager. With her passion for customer centricity, team development and drive to succeed, she rose through the ranks of the organization holding several key leadership positions, including President for China, Head of Global Clinical Labs menu business and Vice President for ASPAC (excluding Japan and China) under Ortho Clinical Diagnostics.

Ms. Lin received a bachelor’s degree from Sun Yat-sen University and an MBA from University of Iowa Tipple College of Business.

Dr. Tamara Ranalli is responsible for defining and executing the strategic vision for the QuidelOrtho molecular and point-of-care diagnostics portfolios. She leads the management of all functions of the business unit in all regions and is accountable for growing revenue and market share worldwide.

Dr. Ranalli joined Quidel in 2010 as an Associate Director for molecular program management. Previous to her current position, she held several key roles including Vice President of Marketing and Senior Vice President of the molecular business unit. During the COVID-19 pandemic, she was instrumental in the successful launch of the Sofia® SARS-CoV-2 Antigen Assay, as well as the Lyra® and Solana® SARS-CoV-2 Molecular Assays. She also recently spearheaded the launch of the Savanna® Instrument, the company’s flagship molecular sample-to-result testing platform.

Dr. Ranalli received a bachelor’s degree in biology from Cornell University and completed her master’s and PhD in biochemistry at University of Rochester School of Medicine.

Karen Taylor oversees all aspects of customer experience, including service, support, commercial excellence and sales enablement. During her more than 26 years with QuidelOrtho and its legacy organizations, she has led several key areas of the business, including sales management, field service and business development. As part of Johnson & Johnson, she managed the divestiture of Ortho Clinical Diagnostics to form an independent operating company under The Carlyle Group.

Ms. Taylor has been instrumental in transforming the customer experience organization and its goal to become the number one rated in vitro diagnostics company for customer satisfaction. She has designed strategies to support continuous improvement, established programs to enable customer feedback, and created training platforms for both customers and employees. Previously, she worked in various roles for Beckman Coulter, BioRad Laboratories and Sanofi Diagnostics.

Ms. Taylor earned a bachelor's degree in medical technology at Illinois State University.

Lisa Hayes drives the company’s brand strategy, marketing initiatives, and communications across all markets and channels, advises the CEO on communications matters and ensures the alignment of the company's narrative with its mission and goals.

With 30 years of healthcare experience, Ms. Hayes is recognized for her strategic mindset, innovative approach, and expertise in developing integrated marketing and communications strategies. She is particularly skilled at uniting cross-disciplinary teams to deliver impactful results.

Throughout her career, she has held senior leadership positions at Ortho Clinical Diagnostics, Prolacta Bioscience, Terumo BCT and Thomson Micromedex. In these roles, she managed corporate strategy and insights, drove M&A integrations, led high-impact marketing campaigns, launched global products, and spearheaded multi-channel communications efforts. Under her leadership, brands have seen measurable growth in market share, customer loyalty, media presence and employee engagement.

Ms. Hayes holds a bachelor’s degree from the School of Communications at the University of Central Florida and has earned multiple certifications related to strategy, marketing, sales, and communications.